Refractory immune thrombocytopenic purpura: Current strategies for investigation and management

  • Psaila B
  • Bussel J
  • 24

    Readers

    Mendeley users who have this article in their library.
  • 52

    Citations

    Citations of this article.

Abstract

There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and highlights emerging therapies, including the thrombopoietic agents, which are anticipated to dramatically alter the natural history of "refractory" ITP. Morbidity, mortality and heath-related quality of life are also discussed.

Author-supplied keywords

  • Bleeding
  • Chronic immune thrombocytopenic purpura
  • Platelet
  • Thrombopoiesis
  • Thrombopoietin

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Bethan Psaila

  • James B. Bussel

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free